Q1 beat and Bio-Techne deal drive upside, but valuation looks full. Read here for a detailed investment analysis.
Merck's Keytruda is the company's biggest growth driver by some margin. In the third quarter, Keytruda's sales increased by 17% year over year to $7.4 billion. Merck's total revenue came in at $16.7 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results